Skip to content
10-K

Annual Report

IMMUNOVANT, INC. IMVT

0001764013-25-000092

← back to feed
Filed
May 29, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · May 23, 2025 170.92M sh
Cash And Equivalents FY 2025 · Mar 31, 2024 $635.37M
Current Liabilities FY 2025 · Mar 31, 2024 $48.61M
Total Liabilities FY 2025 · Mar 31, 2024 $48.61M
Current Assets FY 2025 · Mar 31, 2024 $665.77M
Total Assets FY 2025 · Mar 31, 2024 $666.37M
Shares Diluted FY 2025 · Mar 31, 2023 123.08M sh
Capex FY 2025 · Mar 31, 2023 $197K
Operating Cash Flow FY 2025 · Mar 31, 2023 −$188.19M
Eps Diluted FY 2025 · Mar 31, 2023 −$1.71
Eps Basic FY 2025 · Mar 31, 2023 −$1.71
Sga Expense FY 2025 · Mar 31, 2023 $48.02M
Net Income FY 2025 · Mar 31, 2023 −$210.96M
Stockholders Equity FY 2025 · Mar 31, 2022 $469.83M